🎈 Up Big Today: Find today's biggest gainers with our free screenerTry Stock Screener

Biogen Plunges as Medicare Cover of Alzheimer’s Therapy is Restricted

Published 01/12/2022, 05:47 AM
Updated 01/12/2022, 05:48 AM
© Reuters.
LLY
-
BIIB
-
ESAIY
-
RHHBY
-

By Dhirendra Tripathi

Investing.com – Biogen stock (NASDAQ:BIIB) slumped 9% in Wednesday’s premarket trading after a decision to restrict Medicare coverage of certain alzheimer’s drugs, limiting the scope to generate revenue from its aduhelm drug.

U.S. Centers for Medicare and Medicaid Services, the health agency that runs Medicare, has decided that it will only cover the costs of such drugs for patients enrolled in clinical trials.  The decision is preliminary and the public has a 30-day window to give its comments. A final decision will be taken in April. 

The decision to require the trial "denies nearly all Medicare beneficiaries," Biogen said in a statement. The company warned that if the proposed provision comes to stay, “it would likely take in excess of a year to begin enrolling patients, further delaying reimbursement for Medicare beneficiaries”.

Medicare currently pays for the treatment on a case-to-case basis.

The move to require continued clinical trials for a drug that has already been approved is unusual and reflects the controversy over the Food and Drug Administration's decision to authorize its use in June, which overrode strong objections from some experts on its own advisory panel. They argued that the company needed to place more evidence of the drug’s benefits.

The final CMS coverage terms are expected to apply to all drugs in the class, including experimental medications in development by Eli Lilly (NYSE:LLY), Roche (OTC:RHHBY) and Eisai (OTC:ESALY), Reuters said.

The drug's high price - $56,000 annually - was another sore point and hospitals and doctors backed away from endorsing the treatment because of this. The company has since cut the price to $28,200.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.